Protective effect of N-acetylcysteine on oxaliplatin-induced peripheral neuropathy in colorectal cancer: a randomized controlled trial
Cancer Chemotherapy and Pharmacology · 2026
DOI: 10.1007/s00280-026-04971-0 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Cancer Chemotherapy and Pharmacology, 2026. Verfasst von Zeyad K Hegazy und 2 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacy Department, Faculty of Pharmacy, Tanta University, Tanta, Kafr el Zayat, 31693, Gharbia, Egypt. zeyad_ph_30933357@pharm.tanta.edu.e…. Hauptthemen laut MEDLINE: Peripheral Nervous System Diseases, Acetylcysteine, Colorectal Neoplasms, Oxaliplatin. Die Arbeit nennt 35 Literaturangaben.
Abstract (Originalsprache)
Purpose
Oxaliplatin-induced peripheral neuropathy (OIPN) is a dose-limiting adverse effect of FOLFOX chemotherapy in colorectal cancer (CRC) patients. We aimed to evaluate the protective effect of N-acetylcysteine (NAC) against OIPN. Additionally, we investigated its mechanistic effects on serum biomarkers including total antioxidant capacity (TAC), interleukin-6 (IL-6), and neurotensin.
Methods
Forty-six patients with stage III or high-risk stage II CRC receiving adjuvant modified FOLFOX-6 chemotherapy were randomized in a 1:1 ratio to receive either oral NAC 1200 mg (effervescent tablets or granules) or placebo one hour before each oxaliplatin infusion for four cycles. Serum levels of TAC, IL-6, and neurotensin were measured before and after treatment. Neuropathy was assessed using the FACT/GOG-NTX-12 and NCI-CTCAE scales, and pain was estimated by using the Brief Pain Inventory-Short Form.
Results
Neurotensin was significantly decreased in the NAC group compared to controls after treatment ( P < 0.001), and was significantly lower post-treatment versus pre-treatment in the NAC group ( P = 0.001). IL-6 was significantly reduced in the NAC group versus controls after treatment ( P < 0.001), and significantly decreased post-treatment in both groups ( P < 0.05). FACT/GOG-NTX-12 and NCI-CTCAE scores were significantly lower in the NAC group at the end of the first two cycles and at the end of treatment ( P < 0.05). Pain interference, but not pain severity, was significantly reduced in the NAC group at both time points ( P < 0.001).
Conclusion
NAC administration during FOLFOX chemotherapy significantly reduced OIPN severity, pain interference, and serum levels of IL-6 and neurotensin, suggesting both clinical and mechanistic neuroprotective effects. Clinical Registration The study was is registered on ClinicalTrials.gov (ID: NCT07391163).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Pharmacy Department, Faculty of Pharmacy, Tanta University, Tanta, Kafr el Zayat, 31693, Gharbia, Egypt. zeyad_ph_30933357@pharm.tanta.edu.eg.
- Clinical Pharmacy Department, Faculty of Pharmacy, Tanta University, Tanta, Kafr el Zayat, 31693, Gharbia, Egypt.
- Clinical Oncology Department, Faculty of Medicine, Tanta University, Tanta, Egypt.
Zitieren
APA
Hegazy, Z. K., Tawfik, S. K., & Elmashad, N. M. (2026). Protective effect of N-acetylcysteine on oxaliplatin-induced peripheral neuropathy in colorectal cancer: a randomized controlled trial. Cancer Chemotherapy and Pharmacology. https://doi.org/10.1007/s00280-026-04971-0
Vancouver
Hegazy ZK, Tawfik SK, Elmashad NM. Protective effect of N-acetylcysteine on oxaliplatin-induced peripheral neuropathy in colorectal cancer: a randomized controlled trial. Cancer Chemotherapy and Pharmacology. 2026. doi:10.1007/s00280-026-04971-0
BibTeX
@article{Hegazy2026,
author = {Hegazy, Zeyad K and Tawfik, Sahar K and Elmashad, Nehal M},
title = {Protective effect of N-acetylcysteine on oxaliplatin-induced peripheral neuropathy in colorectal cancer: a randomized controlled trial},
journal = {Cancer Chemotherapy and Pharmacology},
year = {2026},
doi = {10.1007/s00280-026-04971-0}
}
EUVIMED